Group 1 - China is rapidly developing its pharmaceutical industry, particularly in Wuxi, which is becoming a biotechnology hub with numerous factories and laboratories [1] - Chinese biotechnology companies are able to conduct drug testing and production significantly faster than their American counterparts, leading to lower drug prices for consumers [2] - The Chinese government is providing strong support for the biotechnology sector, which includes a growing workforce of scientists and collaborations with foreign companies [2][3] Group 2 - Recent reforms by the National Medical Products Administration in China have reduced the waiting time for clinical trial approvals and lowered operational costs by approximately 30% compared to the U.S. [3] - China's biotechnology industry is part of its strategy to expand global soft power, with increasing exports of pharmaceuticals to Southeast Asian countries [3] - The rise of China's biotechnology sector is viewed by some as a threat, but it may also provide solutions to high prescription drug prices in the U.S., offering more affordable treatment options for diseases [2][3]